Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer
2021 ◽
Vol 30
(3)
◽
pp. 253-263
2018 ◽
Vol 9
(36)
◽
pp. 24237-24247
◽
Chih-Yen Tu
◽
Chuan-Mu Chen
◽
Wei-Chih Liao
◽
Biing-Ru Wu
◽
Chih-Yu Chen
◽
...
2015 ◽
Vol 33
(15_suppl)
◽
pp. e19124-e19124
Yukio Hosomi
◽
Chiharu Tanai
◽
Kiyotaka Yoh
◽
Yasushi Goto
◽
Yasuo Ohashi
◽
...
2017 ◽
Vol 5
(1)
◽
pp. 11-11
Shinkyo Yoon
◽
Dae Ho Lee
◽
Sang-We Kim
J. von Pawel
◽
R. Pirker
◽
J.R. Pereira
◽
M. Krzakowski
◽
K. Park
◽
...
2006 ◽
Vol 95
(8)
◽
pp. 998-1004
◽
H Asahina
◽
◽
K Yamazaki
◽
I Kinoshita
◽
N Sukoh
◽
...
2011 ◽
Vol 14
(3)
◽
pp. A82
◽
W. Chen
◽
P. Ellis
◽
L. Levin
◽
M. Krahn
2016 ◽
Vol 19
(7)
◽
pp. A720
VV Ryazhenov
◽
SG Gorokhova
◽
V Gorokhov
2015 ◽
Vol 26
(9)
◽
pp. 995-1003
◽
Sávia R.C. Normando
◽
Felipe M. Cruz
◽
Auro del Giglio
2011 ◽
Vol 3
◽
pp. RRN1245
◽
Naoko Ishibe
◽
Josh Carlson
◽
Scott David Ramsey
◽
Andrew Freedman
◽
Sheri Schully
2011 ◽
Vol 47
◽
pp. S591
◽
K. O'Bvrne
◽
L. Paz-Ares
◽
J.R. Pereira
◽
J. von Pawel
◽
R. Ramlau
◽
...
Close
Export Citation Format
Close
Share Document
Close